685111-87-9

Basic information

• Product Name: 1,3-Propanediol, 1-(4-pyridinyl)-, (1S)-
• CAS NO: 685111-87-9
• Molecular Formula: C8H11NO2
• Molecular Weight: 153.181
• Mol File: 685111-87-9.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 1,3-Propanediol, 1-(4-pyridinyl)-, (1S)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-Propanediol, 1-(4-pyridinyl)-, (1S)-(685111-87-9)
• EPA Substance Registry System: 1,3-Propanediol, 1-(4-pyridinyl)-, (1S)-(685111-87-9)

Safety Data

• Hazardous Substances Data: 685111-87-9(Hazardous Substances Data)

Usage

Explanation

The molecular formula representing the compound's composition of carbon (C), hydrogen (H), nitrogen (N), and oxygen (O) atoms.

Explanation

It is derived from 1,3-propanediol, a common alcohol used in various industrial applications.
3. Presence of 4-pyridinyl group

Explanation

The compound contains a 4-pyridinyl group, which imparts specific properties to the compound.
4. Use in organic synthesis

Explanation

Due to its unique properties, the compound serves as a building block in organic synthesis.
5. Application in pharmaceutical research

Explanation

The compound is useful in pharmaceutical research, potentially leading to the development of new drugs.
6. Potential health hazards

Explanation

It should be handled with care due to its potential to cause irritation to the skin, eyes, and respiratory system upon contact.

Explanation

The compound has a range of potential applications across these scientific disciplines.

Derivative of

1,3-propanediol

Fields of application

Chemistry, biology, and materials science

Upstream product

• 676563-15-8 ethyl (S)-3-hydroxy-3-(pyridin-4-yl)propanoate 
• 26377-17-3 ethyl 3-oxo-3-(4-pyridyl)propanoate 
• 1570-45-2 isonicotinic acid ethylester 
• 55-22-1 pyridine-4-carboxylic acid 
• 872-85-5 pyridine-4-carbaldehyde 
• 108-05-4 vinyl acetate 
• 591228-10-3 methyl 3-hydroxy-3-(pyridin-4-yl)-propanoate 
• 676563-14-7 (S)(-)methyl-3-hydroxy-3-(pyridin-4-yl)-propanote 
• 591228-11-4 3-hydroxy-3-(pyridin-4-yl)propionic acid ethyl ester 
• 1026885-94-8 ethyl 3-(L-2-N,N-dimethylamino-3-phenyl-propanoyloxy)-3-(pyridin-4-yl)-propanoate 

Downstream Products

• 1192264-91-7 trans-4-[(S)-pyridin-4-yl]-2-(4-nitrophenoxy)-2-oxo-1,3,2-dioxaphosphorinane 
• 685111-88-0 (-)-(4S)-trans-2-(4-nitrophenoxy)-2-oxido-4-(pyridin-4-yl)-1,3,2-dioxaphosphorinane 
• 685111-92-6 (4S)-5'-O-cis-[4-(pyridin-4yl)-2-oxido-1,3,2-dioxaphosphorinan-2yl]-cytosine-β-D-arabinofuranoside 

Relevant articles and documents

Development of a Novel Chemoenzymatic Process for (S)-1-(Pyridin-4-yl)-1,3-propanediol

We first developed a novel and efficient chemoenzymatic process to prepare (S)-1-(pyridin-4-yl)-1,3-propanediol, a vital HepDirect prodrug intermediate, from inexpensive and commercially available isonicotinic acid. Through this process, we provide a creative way to obtain the key chiral intermediate, β-hydroxyester, with ketoreductase (KRED) EA. After optimization of the process, we performed the reaction on a 100 g scale with a substrate concentration of up to 150 g/L, a yield of 93%, and an ee value of up to 99.9%. Additionally, we used a simple and effective NaBH4/MgCl2 reduction system to obtain (S)-1-(pyridin-4-yl)-1,3-propanediol with >99.9% ee and an 80% yield. This novel chemoenzymatic process has the potential to be a cost-effective and environmentally friendly process suitable for industrial use.

Chiral primary amine catalyzed asymmetric direct cross-aldol reaction of acetaldehyde

The first primary aminocatalytic direct cross-aldol reaction of acetaldehyde is presented. Among the various vicinal diamines screened, the L-tert-leucine derivative 1c in conjunction with (H4SiW 12O40)0.25 was identified as the optimal catalyst; good catalytic activity (up to 99% yield in 4 h), and high enantioselectivities (up to 92% ee) were achieved for a range of donors, including aromatic aldehydes and isatin derivatives. Aqueous acetaldehyde solution and paraldehyde can be conveniently applied in this system.

Synthesis and characterization of a novel liver-targeted prodrug of cytosine-1-β-D-arabinofuranoside monophosphate for the treatment of hepatocellular carcinoma

Cytotoxic nucleosides have proven to be ineffective for the treatment of hepatocellular carcinoma (HCC) due, in part, to their inadequate conversion to their active nucleoside triphosphates (NTP) in the liver tumor and high conversion in other tissues. Th